Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × Thyroxine × Clear all

Phase

Phase NA 4 Phase 2 3 Phase 3 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Postoperative Complications 1 Neoplasms 1 Hypothyroidism 1

Interventions

Cisplatin 48 Fluorouracil 41 Cyclophosphamide 40 Oxaliplatin 36 Capecitabine 33 Docetaxel 32 Drug Therapy 29 Gemcitabine 28 Radiotherapy 26 Paclitaxel 24 Leucovorin 21 Carboplatin 21 Dexamethasone 19 Doxorubicin 17 apatinib 15 Etoposide 15 Cytarabine 15 Methotrexate 14 Magnetic Resonance Spectroscopy 13 Epirubicin 13 Radiation 12 Busulfan 12 Letrozole 11 Decitabine 11 Bevacizumab 11 camrelizumab 10 Surgical Procedures, Operative 10 Neoadjuvant Therapy 10 Irinotecan 10 Folfox protocol 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02548715 2022-07-13

LSHT

University of Alberta

Phase 2/3 Withdrawn

Hypothyroidism, Neoplasms, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡